EcoR1 Capital, LLC bought $1.0M of AnaptysBio (ANAB)
Executed Dec 30 2024, disclosed Jan 2 2025, 3 days later.
Over the 21 trading sessions from the disclosed entry session (Jan 2 2025), the stock returned +24.1% (delay-adjusted); from the execution session (Dec 30 2024), +35.4%. Derived: entry at the session's open, exit at the close 20 sessions later.
EcoR1 Capital, LLC (Director) filed 2 Form 4 reports as a reporting entity in the trailing twelve months (2 purchases, 0 sales), most often in Zymeworks Inc. (ZYME). Across 2 priced purchase filings, the average 21-session return was +2.8% from execution and -5.0% from disclosure (delay-adjusted; derived). The largest single filing was $40.0M of AKTS (2,222,222 sh across 2 lots, as filed), executed Jan 12.
Healthcare · AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→